{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:06:12Z","timestamp":1789542372438,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review examines approaches to primary cardiovascular prevention in people with HIV (PWH), focusing on the implications of the REPRIEVE trial and the 2026 ACC\/AHA multisociety dyslipidemia guideline. We discuss cardiovascular risk mechanisms, limitations of conventional prediction tools, selection and monitoring of statin therapy, and the potential roles of imaging and non-statin lipid-lowering agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>REPRIEVE demonstrated that pitavastatin reduced major adverse cardiovascular events in PWH aged 40\u201375 years receiving antiretroviral therapy and at low-to-moderate estimated cardiovascular risk. Absolute benefit varied substantially according to baseline risk. Current US guidance recommends statin therapy for primary prevention in PWH aged 40\u201375 years receiving stable combination antiretroviral therapy, while quantitative risk assessment remains important for communicating expected benefit and informing treatment intensity. REPRIEVE did not directly study PWH younger than 40 years or older than 75 years; however, cohort data suggest a higher HIV-attributable relative cardiovascular risk at younger ages despite low absolute event rates, whereas general-population evidence supports statin efficacy and acceptable tolerability in older adults. Conventional risk models show variable performance in PWH, and high-quality evidence supporting imaging-guided prevention or non-statin cardiovascular outcome reduction specifically in this population remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Statin therapy is an evidence-based component of primary cardiovascular prevention in PWH aged 40\u201375 years, but guideline-level eligibility does not imply uniform absolute benefit. Outside the REPRIEVE age range, decisions should integrate the distinct balance of relative and absolute risk, general-population evidence, comorbidity, frailty, drug\u2013drug interactions, treatment burden, and individual preferences rather than rely on age alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-026-00797-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:42:12Z","timestamp":1789540932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Cardiovascular Prevention in People Living With HIV: Rethinking Statin Therapy in the Post-REPRIEVE Era"],"prefix":"10.1007","volume":"23","author":[{"given":"Paolo","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"8","key":"797_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614\u201322. https:\/\/doi.org\/10.1001\/jamainternmed.2013.3728.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"797_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11904-013-0168-6","volume":"10","author":"VA Triant","year":"2013","unstructured":"Triant VA. Cardiovascular disease and HIV infection. Curr HIV\/AIDS Rep. 2013;10(3):199\u2013206. https:\/\/doi.org\/10.1007\/s11904-013-0168-6.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"797_CR3","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019;140(2):e98\u2013124. https:\/\/doi.org\/10.1161\/CIR.0000000000000695.","journal-title":"Circulation"},{"issue":"9","key":"797_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/QAD.0b013e32832b514b","volume":"23","author":"PY Hsue","year":"2009","unstructured":"Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059\u201367. https:\/\/doi.org\/10.1097\/QAD.0b013e32832b514b.","journal-title":"AIDS"},{"issue":"10","key":"797_CR5","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, Tracy R, Belloso W, INSIGHT SMART Study Group, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https:\/\/doi.org\/10.1371\/journal.pmed.0050203.","journal-title":"PLoS Med"},{"issue":"9","key":"797_CR6","doi-asserted-by":"publisher","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","volume":"7","author":"DA Duprez","year":"2012","unstructured":"Duprez DA, Neuhaus J, Kuller LH, INSIGHT SMART Study Group, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE. 2012;7(9):e44454. https:\/\/doi.org\/10.1371\/journal.pone.0044454.","journal-title":"PLoS ONE"},{"issue":"7","key":"797_CR7","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1210\/jc.2006-2190","volume":"92","author":"VA Triant","year":"2007","unstructured":"Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506\u201312. https:\/\/doi.org\/10.1210\/jc.2006-2190.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"797_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/jamacardio.2016.5139","volume":"2","author":"HM Crane","year":"2017","unstructured":"Crane HM, Paramsothy P, Drozd DR, et al. Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. JAMA Cardiol. 2017;2(3):260\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2016.5139.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"797_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11904-021-00567-w","volume":"18","author":"AC Achhra","year":"2021","unstructured":"Achhra AC, Lyass A, Borowsky L, et al. Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. Curr HIV\/AIDS Rep. 2021;18(4):271\u20139. https:\/\/doi.org\/10.1007\/s11904-021-00567-w.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"797_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, et al. REPRIEVE Trial Investigators. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023;389(8):687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2304146.","journal-title":"N Engl J Med"},{"issue":"5","key":"797_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.7326\/M14-0954","volume":"162","author":"R Mdodo","year":"2015","unstructured":"Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335\u201344. https:\/\/doi.org\/10.7326\/M14-0954.","journal-title":"Ann Intern Med"},{"issue":"6","key":"797_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A, INSIGHT SMART Study Group, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780\u201390. https:\/\/doi.org\/10.1093\/infdis\/jiq118.","journal-title":"J Infect Dis"},{"issue":"2","key":"797_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/QAD.0b013e328333ea9e","volume":"24","author":"J Lo","year":"2010","unstructured":"Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243\u201353. https:\/\/doi.org\/10.1097\/QAD.0b013e328333ea9e.","journal-title":"AIDS"},{"issue":"9622","key":"797_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(08)60423-7.","journal-title":"Lancet"},{"issue":"4","key":"797_CR15","doi-asserted-by":"publisher","first-page":"ofaf177","DOI":"10.1093\/ofid\/ofaf177","volume":"12","author":"E Davies Smith","year":"2025","unstructured":"Davies Smith E, Malvestutto C, Ribaudo HJ, et al. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025;12(4):ofaf177. https:\/\/doi.org\/10.1093\/ofid\/ofaf177.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"797_CR16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"797_CR17","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","volume":"5","author":"L Ryom","year":"2018","unstructured":"Ryom L, Lundgren JD, El-Sadr W, et al. D:A:D Study Group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291\u2013300. https:\/\/doi.org\/10.1016\/S2352-3018(18)30043-2.","journal-title":"Lancet HIV"},{"key":"797_CR18","unstructured":"European AIDS, Clinical Society (EACS). EACS Guidelines, Version 13.0. October 2025. Available at: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/. Accessed 1 Aug 2026."},{"issue":"13","key":"797_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/01.CIR.0000124480.32233.8A","volume":"109","author":"PY Hsue","year":"2004","unstructured":"Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13):1603\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000124480.32233.8A.","journal-title":"Circulation"},{"issue":"2","key":"797_CR20","doi-asserted-by":"publisher","first-page":"e000422","DOI":"10.1161\/JAHA.111.000422","volume":"1","author":"PY Hsue","year":"2012","unstructured":"Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012;1(2):e000422. https:\/\/doi.org\/10.1161\/JAHA.111.000422.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"797_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","volume":"115","author":"MW Lorenz","year":"2007","unstructured":"Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459\u201367. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.628875.","journal-title":"Circulation"},{"issue":"1","key":"797_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/QAI.0000000000002400","volume":"85","author":"B Pereira","year":"2020","unstructured":"Pereira B, Mazzitelli M, Milinkovic A, et al. Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIV. J Acquir Immune Defic Syndr. 2020;85(1):98\u2013105. https:\/\/doi.org\/10.1097\/QAI.0000000000002400.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"19","key":"797_CR23","doi-asserted-by":"publisher","first-page":"e019291","DOI":"10.1161\/JAHA.120.019291","volume":"10","author":"C Soares","year":"2021","unstructured":"Soares C, Samara A, Yuyun MF, et al. Coronary Artery Calcification and Plaque Characteristics in People Living With HIV: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021;10(19):e019291. https:\/\/doi.org\/10.1161\/JAHA.120.019291.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"797_CR24","first-page":"734","volume":"100","author":"J Mandrola","year":"2019","unstructured":"Mandrola J, Foy A. The Case Against Coronary Artery Calcium Scoring for Cardiovascular Disease Risk Assessment. Am Fam Physician. 2019;100(12):734\u20135.","journal-title":"Am Fam Physician"},{"issue":"19","key":"797_CR25","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","volume":"87","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624\u2013757. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"797_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12879-021-05787-4","volume":"21","author":"H Drechsler","year":"2021","unstructured":"Drechsler H, Ayers C, Cutrell J, Arasaratnam R, Bedimo R. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. BMC Infect Dis. 2021;21(1):150. https:\/\/doi.org\/10.1186\/s12879-021-05787-4.","journal-title":"BMC Infect Dis"},{"issue":"14","key":"797_CR27","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1097\/QAD.0000000000001167","volume":"30","author":"CT Longenecker","year":"2016","unstructured":"Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195\u2013203. https:\/\/doi.org\/10.1097\/QAD.0000000000001167.","journal-title":"AIDS"},{"issue":"4","key":"797_CR28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/QAI.0000000000000478","volume":"68","author":"NT Funderburg","year":"2015","unstructured":"Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396\u2013404. https:\/\/doi.org\/10.1097\/QAI.0000000000000478.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"797_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","volume":"9","author":"MT Lu","year":"2024","unstructured":"Lu MT, Ribaudo H, Foldyna B, REPRIEVE Trial Writing Group, et al. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2024;9(4):323\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.5661.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"797_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamacardio.2024.4115","volume":"10","author":"M Kolossv\u00e1ry","year":"2025","unstructured":"Kolossv\u00e1ry M, Schnittman SR, Zanni MV, et al. Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2025;10(3):254\u201364. https:\/\/doi.org\/10.1001\/jamacardio.2024.4115.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"797_CR31","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, JUPITER Study Group, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"issue":"10170","key":"797_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(18)31942-1.","journal-title":"Lancet"},{"issue":"3","key":"797_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40266-019-00736-y","volume":"37","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Albarqouni L, Curtis AJ, Breslin M, Nelson M. The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging. 2020;37(3):175\u201385. https:\/\/doi.org\/10.1007\/s40266-019-00736-y.","journal-title":"Drugs Aging"},{"issue":"1","key":"797_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"797_CR35","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350.2018 AHA\/ACC\/AACVPR\/AAPA. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003. \/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA. 2018 AHA\/ACC\/AACVPR\/AAPA.","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"797_CR36","unstructured":"Panel for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. Updated May 27. 2026. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv. Accessed August 1, 2026."},{"issue":"23 Suppl 1","key":"797_CR37","doi-asserted-by":"publisher","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39\u201343. https:\/\/doi.org\/10.1161\/01.CIR.0000131517.20177.5a.","journal-title":"Circulation"},{"issue":"25","key":"797_CR38","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"18","key":"797_CR39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"797_CR40","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"15","key":"797_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"key":"797_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12944-015-0054-x","volume":"14","author":"R Saeedi","year":"2015","unstructured":"Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14:57. https:\/\/doi.org\/10.1186\/s12944-015-0054-x.","journal-title":"Lipids Health Dis"},{"issue":"20","key":"797_CR43","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","volume":"75","author":"F Boccara","year":"2020","unstructured":"Boccara F, Kumar PN, Caramelli B, et al. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. J Am Coll Cardiol. 2020;75(20):2570\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.025.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"797_CR44","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","volume":"9","author":"PWG Mallon","year":"2022","unstructured":"Mallon PWG, Brunet L, Hsu RK, et al. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infect Dis. 2022;9(1):ofab621. https:\/\/doi.org\/10.1093\/ofid\/ofab621.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"797_CR45","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1093\/cid\/ciag196","volume":"83","author":"JR Koethe","year":"2026","unstructured":"Koethe JR, Lake JE, Kantor A, et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026;83(1):e81\u20139. https:\/\/doi.org\/10.1093\/cid\/ciag196.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"797_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455\u201365. https:\/\/doi.org\/10.1097\/QAD.0000000000002223.","journal-title":"AIDS"},{"issue":"23","key":"797_CR47","doi-asserted-by":"publisher","first-page":"e035975","DOI":"10.1161\/JAHA.124.035975","volume":"13","author":"DS Kikuchi","year":"2024","unstructured":"Kikuchi DS, Kwapong YA, Sch\u00e4r M, et al. Lipoprotein(a) Is Elevated and Inversely Related to Coronary Endothelial Function in People With HIV. J Am Heart Assoc. 2024;13(23):e035975. https:\/\/doi.org\/10.1161\/JAHA.124.035975.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"797_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/QAD.0000000000004349","volume":"40","author":"TT Stoltz","year":"2026","unstructured":"Stoltz TT, Jensen AMR, Roed AKH, et al. Plasma levels of lipoprotein(a) in persons with HIV compared to the general population. AIDS. 2026;40(1):35\u201342. https:\/\/doi.org\/10.1097\/QAD.0000000000004349.","journal-title":"AIDS"},{"issue":"11","key":"797_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","volume":"134","author":"LM Obare","year":"2024","unstructured":"Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease. Circ Res. 2024;134(11):1515\u201345. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323891.","journal-title":"Circ Res"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00797-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:42:15Z","timestamp":1789540935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00797-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00797-w","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Compliance with Ethical Standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28"}}